세계의 근육긴장이상 치료제 시장 규모 조사 및 예측 : 약물 유형별, 투여 경로별, 유통 채널별, 지역별 분석(2022-2029년)

Global Dystonia Drugs Market is valued at approximately USD 806.7 million in 2021 and is anticipated to grow with a healthy growth rate of more than 5.5% over the forecast period 2022-2029. Dystonia may be classified as a movement disorder that is characterized by involuntary muscle contractions that cause slow repetitive motions or abnormal postures. These muscular contractions cause unusual body postures and movements. Different types of dystonia might affect a single muscle, a group of muscles, or the entire body's muscles. It is caused by disorders including birth-related brain injury, certain infections, brain trauma, or different vascular abnormalities such as stroke, arteriovenous, and others. It makes patients' movements unpleasant or might cause tremors. Although dystonia does not have a specific treatment, some drugs can help to ease its symptoms. The expansion of the dystonia drugs market is anticipated to be driven by significant upside in untapped, emerging markets, owing to availability of strengthening healthcare infrastructure, rising unmet health care requirements, and an increase in demand for advanced healthcare facilities. The market is expanding due to a rise in both the incidence of dystonia and the prevalence of other neurological illnesses with symptoms similar to dystonia. The market for drugs for dystonia is also expanding as a result of an increase in R&D activity in both developed and developing nations. Researchers' efforts to develop and invent new medicines for the treatment of various medical diseases have significantly increased. The development of new, highly potent drug molecules is the main area of research at present. Drug development innovations are also being used to provide potent dystonia drug treatments. Thus, a rise in this research is fueling the market for drugs for dystonia.

As per National Organization for Rare Disorders, Inc. (NORD), in 2020 stated that there were 300,000 persons in North America who were affected by different types of dystonia. The prevalence of dystonia is increasing, which raises the need for drugs to treat it and fuels the market share growth of drugs for dystonia. Additionally, the rising investment in the healthcare sector and cohesive government support is anticipated to create a lucrative opportunity for the market. However, the lack of awareness about dystonia stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Dystonia Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the presence of key market players, increasing incidences of dystonia along with the rising prevalence of other neurological conditions causing dystonia. Whereas, Asia Pacific is also anticipated to exhibit the highest growth rate over the forecast period, owing to factors such as rising infrastructure of industries, and increasing disposable incomes, as well as the well-established presence of domestic companies in the region, would create lucrative growth prospects for the Dystonia Drugs market across Asia Pacific region.

Major market players included in this report are:

• Pfizer Inc

• Novartis AG

• Sanofi

• Merck & Co Inc

• Aspan Holdings

• China Shineway Pharmaceutical Group Limited

• Boston Scientific Corporation

• Ipsen Pharma

• Revance therapeutics Inc

• Merz Pharma

Recent Developments in the Market:

• In June 2022, Amneal Pharmaceuticals, Inc. announced the launch of LYVISPAH, a baclofen oral granules specialized product approved by the U.S. Food and Drug Administration for diagnosis of spasticity related to multiple sclerosis and some other spinal cord disorders.

Global Dystonia Drugs Market Report Scope:

• Historical Data: 2019-2020-2021

• Base Year for Estimation: 2021

• Forecast period: 2022-2029

• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends

• Segments Covered: Drug Type, Route of Administration, Distribution Channel, Region

• Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World

• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Drug Type:

• Anticonvulsants drugs
• Dopaminergic agents
• GABAergic agents
• Others

By Route of Administration:

• Oral
• Injectable

By Distribution Channel:

• Hospital Pharmacies
• Online Providers
• Drug Stores and Retail Pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• RoLA
• Rest of the World

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Million)
  • 1.2.1. Dystonia Drugs Market, by Region, 2019-2029 (USD Million)
  • 1.2.2. Dystonia Drugs Market, by Drug Type, 2019-2029 (USD Million)
  • 1.2.3. Dystonia Drugs Market, by Route of Administration, 2019-2029 (USD Million)
  • 1.2.4. Dystonia Drugs Market, by Distribution Channel, 2019-2029 (USD Million)
• 1.3. Estimation Methodology
• 1.4. Research Assumption

Chapter 2. Global Dystonia Drugs Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Dystonia Drugs Market Dynamics

• 3.1. Dystonia Drugs Market Impact Analysis (2019-2029)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Rise in incidences of dystonia
    • 3.1.1.2. Increasing R&D activities in pharmaceutical field
  • 3.1.2. Market Challenges
    • 3.1.2.1. Lack of awareness about dystonia in underdeveloped nations
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Rising investment in healthcare sector
    • 3.1.3.2. Cohesive government support

Chapter 4. Global Dystonia Drugs Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
• 4.4. Top investment opportunity
• 4.5. Top winning strategies
• 4.6. Industry Experts Prospective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1. Assessment of the overall impact of COVID-19 on the industry
• 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Dystonia Drugs Market, by Drug Type

• 6.1. Market Snapshot
• 6.2. Global Dystonia Drugs Market by Drug Type, Performance - Potential Analysis
• 6.3. Global Dystonia Drugs Market Estimates & Forecasts by Drug Type 2019-2029 (USD Million)
• 6.4. Dystonia Drugs Market, Sub Segment Analysis
  • 6.4.1. Anticonvulsants drugs
  • 6.4.2. Dopaminergic agents
  • 6.4.3. GABAergic agents
  • 6.4.4. Others

Chapter 7. Global Dystonia Drugs Market, by Route of Administration

• 7.1. Market Snapshot
• 7.2. Global Dystonia Drugs Market by Route of Administration, Performance - Potential Analysis
• 7.3. Global Dystonia Drugs Market Estimates & Forecasts by Route of Administration 2019-2029 (USD Million)
• 7.4. Dystonia Drugs Market, Sub Segment Analysis
  • 7.4.1. Oral
  • 7.4.2. Injectable

Chapter 8. Global Dystonia Drugs Market, by Distribution Channel

• 8.1. Market Snapshot
• 8.2. Global Dystonia Drugs Market by Distribution Channel, Performance - Potential Analysis
• 8.3. Global Dystonia Drugs Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Million)
• 8.4. Dystonia Drugs Market, Sub Segment Analysis
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Online Providers
  • 8.4.3. Drug Stores and Retail Pharmacies

Chapter 9. Global Dystonia Drugs Market, Regional Analysis

• 9.1. Dystonia Drugs Market, Regional Market Snapshot
• 9.2. North America Dystonia Drugs Market
  • 9.2.1. U.S. Dystonia Drugs Market
    • 9.2.1.1. Drug Type breakdown estimates & forecasts, 2019-2029
    • 9.2.1.2. Route of Administration breakdown estimates & forecasts, 2019-2029
    • 9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
  • 9.2.2. Canada Dystonia Drugs Market
• 9.3. Europe Dystonia Drugs Market Snapshot
  • 9.3.1. U.K. Dystonia Drugs Market
  • 9.3.2. Germany Dystonia Drugs Market
  • 9.3.3. France Dystonia Drugs Market
  • 9.3.4. Spain Dystonia Drugs Market
  • 9.3.5. Italy Dystonia Drugs Market
  • 9.3.6. Rest of Europe Dystonia Drugs Market
• 9.4. Asia-Pacific Dystonia Drugs Market Snapshot
  • 9.4.1. China Dystonia Drugs Market
  • 9.4.2. India Dystonia Drugs Market
  • 9.4.3. Japan Dystonia Drugs Market
  • 9.4.4. Australia Dystonia Drugs Market
  • 9.4.5. South Korea Dystonia Drugs Market
  • 9.4.6. Rest of Asia Pacific Dystonia Drugs Market
• 9.5. Latin America Dystonia Drugs Market Snapshot
  • 9.5.1. Brazil Dystonia Drugs Market
  • 9.5.2. Mexico Dystonia Drugs Market
  • 9.5.3. Rest of Latin America Dystonia Drugs Market
• 9.6. Rest of The World Dystonia Drugs Market

Chapter 10. Competitive Intelligence

• 10.1. Top Market Strategies
• 10.2. Company Profiles
  • 10.2.1. Pfizer Inc
    • 10.2.1.1. Key Information
    • 10.2.1.2. Overview
    • 10.2.1.3. Financial (Subject to Data Availability)
    • 10.2.1.4. Product Summary
    • 10.2.1.5. Recent Developments
  • 10.2.2. Novartis AG
  • 10.2.3. Sanofi
  • 10.2.4. Merck & Co, Inc
  • 10.2.5. Aspan Holdings
  • 10.2.6. China Shineway Pharmaceutical Group Limited
  • 10.2.7. Boston Scientific Corporation
  • 10.2.8. Ipsen Pharma
  • 10.2.9. Revance therapeutics Inc
  • 10.2.10. Merz Pharma

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes
• 11.3. Research Assumption